Free Trial

Taysha Gene Therapies (TSHA) Earnings Date, Estimates & Call Transcripts

Taysha Gene Therapies logo
$2.75 +0.31 (+12.70%)
Closing price 04:00 PM Eastern
Extended Trading
$2.74 -0.01 (-0.36%)
As of 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Taysha Gene Therapies Earnings Summary

Taysha Gene Therapies issued Q1 2025 earnings on May 15, 2025, reporting an EPS of -$0.08, which hit the consensus estimate of -$0.08. Quarterly revenue was reported to be $2.30 million, above the consensus estimate of $1.48 million. With a trailing EPS of -$0.34 and a P/E Ratio of 4.37, Taysha Gene Therapies' earnings are expected to decrease next year, from ($0.35) to ($0.37) per share.

Upcoming Q2
Earnings Date
Aug. 11Before Market OpensEstimated
Consensus EPS
(May. 15)
-$0.08
Actual EPS
(May. 15)
-$0.08
Actual Revenue
(May. 15)
$2.30M

Q1 2025 Earnings Resources

TSHA Upcoming Earnings

Taysha Gene Therapies' next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules.

Get Taysha Gene Therapies Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Taysha Gene Therapies and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

TSHA Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

TSHA Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Taysha Gene Therapies Analyst EPS Estimates

Current Year EPS Consensus Estimate
($0.35) EPS
Next Year EPS Consensus Estimate
($0.37) EPS

Taysha Gene Therapies Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
8/11/2025
(Estimated)
--------
5/15/2025Q1 2025-$0.08-$0.08--$0.08$1.48M$2.30M
2/26/2025Q4 2024-$0.08-$0.07+$0.01-$0.07$2.05M$2.02M
8/12/2024Q2 2024-$0.10-$0.09+$0.01-$0.09$3.62M$1.11M
5/14/2024Q1 2024-$0.11-$0.10+$0.01-$0.10$3.70M$3.41M
3/19/2024Q4 2023-$0.35+$0.35-$0.22$4.75M$3.60M
11/14/2023Q3 2023-$0.13-$0.13-$0.67$2.65M$4.75M
8/14/2023Q2 2023-$0.31-$0.38 -$0.07-$0.38$2.00M$2.40M

Taysha Gene Therapies Earnings - Frequently Asked Questions

Taysha Gene Therapies has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 11th, 2025 based off last year's report dates. Learn more on TSHA's earnings history.

In the previous quarter, Taysha Gene Therapies (NASDAQ:TSHA) reported ($0.08) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.08). Learn more on analysts' earnings estimate vs. TSHA's actual earnings.

The conference call for Taysha Gene Therapies's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Taysha Gene Therapies's latest earnings report can be read online.
Read Transcript

Taysha Gene Therapies (NASDAQ:TSHA) has a recorded annual revenue of $7.22 million.

Taysha Gene Therapies (NASDAQ:TSHA) has a recorded net income of -$111.57 million. TSHA has generated -$0.34 earnings per share over the last four quarters.

Taysha Gene Therapies (NASDAQ:TSHA) has a trailing price-to-earnings ratio of 4.39.

Taysha Gene Therapies's earnings are expected to decrease from ($0.35) per share to ($0.37) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:TSHA) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners